Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1′-cyclohexan]-4′-yl]benzimidazole NPY Y5 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 18, 2008, Pages 4997-5001

  Ogino, Yoshio ^a   Ohtake, Norikazu ^a   Nagae, Yoshikazu ^a   Matsuda, Kenji ^a   Ishikawa, Makoto ^a   Moriya, Minoru ^a   Kanesaka, Maki ^a   Mitobe, Yuko ^a   Ito, Junko ^a   Kanno, Tetsuya ^a   Ishihara, Akane ^a   Iwaasa, Hisashi ^a   Ohe, Tomoyuki ^a   Kanatani, Akio ^a   Fukami, Takehiro ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antagonist; Anti obesity; Benzimidazole; Neuropeptide Y; Y5 receptor

Indexed keywords

1 METHYL 5,6 DICHLOROBENZIMIDAZOLE; 2 [3 OXOSPIRO(ISOBENZOFURAN 1(3H),1' CYCLOHEXAN) 4' YL]BENZIMIDAZOLE; 5 (2 METHYLTETRAZOL 5 YL)BENZIMIDAZOLE; 5 (5 METHYL 1,2,4 OXADIAZOL 2 YL)BENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y5 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; BENZIMIDAZOLES; BRAIN; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 51349130429     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.021     Document Type: Article

References (26)

1. Tatemoto K., and Mutt M. Nature 285 (1980) 417
2. Tatemoto K., Carlquist M., and Mutt V. Nature 296 (1982) 659
3. Blomqvist A.G., and Herzog H. Trends Neurosci. 20 (1997) 294
4. Gerald C., Walker M.W., Criscione L., Gustafson E.L., Batzl-Hartmann C., Smith K.E., Vaysse P., Durkin M.M., Laz T.M., Linemeyer D.L., Schaffhauser A.O., Whitebread S., Hofbauer K.G., Taber R.I., Branchek T.A., and Weinshank R.L. Nature 382 (1996) 168
5. Kanatani A., Ishihara A., Iwaasa H., Nakamura K., Okamoto O., Hidaka M., Ito J., Fukuroda T., MacNeil D.J., Van der Ploeg H.T., Lex Ishii Y., Okabe T., Fukami T., and Ihara M. Biochem. Biophys. Res. Commun. 272 (2000) 169
6. Ishihara A., Kanatani A., Mashiko S., Tanaka T., Hidaka M., Gomori A., Iwaasa H., Murai N., Egashira S., Murai T., Mitobe Y., Matsushita H., Okamoto O., Sato N., Jitsuoka M., Fukuroda T., Ohe T., Guan X., MacNeil D.J., Van der Ploeg L.H.T., Nishikibe M., Ishii Y., Ihara M., and Fukami T. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7154
7. Rueeger H., Rigollier P., Yamaguchi Y., Schmidlin T., Shilling W.M., Criscione L., Whitebread S., Chiesi M., Walker M.W., Dhanoa D., Islam I., Zhang J., and Gluchowski C. Bioorg. Med. Chem. Lett. 10 (2000) 1175
8. Youngman M.A., McNally J.J., Lovenberg T.W., Reitz A.B., Willard N.M., Nepomuceno D.H., Wilson S.J., Crooke J.J., Rosenthal D., Vaidya A.H., and Dax S.L. J. Med. Chem. 43 (2000) 346
9. Norman M.H., Chen N., Chen Z., Fotsch C., Hale C., Han N., Hurt R., Jenkins T., Kincaid J., Liu L., Liu Y., Moreno O., Santora V.J., Sonnenberg J.D., and Karbon W. J. Med. Chem. 43 (2000) 4288
10. Itani H., Ito H., Sakata Y., Hatakeyama Y., Oohashi H., and Satoh Y. Bioorg. Med. Chem. Lett. 12 (2002) 799
11. Block M.H., Boyer S., Brailsford W., Brittain D.R., Carroll D., Chapman S., Clarke D.S., Donald C.S., Foote K.M., Godfrey L., Lander A., Marsham P.R., Masters D.J., Mee C.D., O'donovan M.R., Pease J.E., Pickup A.G., Rayner J.W., Roberts A., Schofield P., Suleman A., and Turnbull A.V. J. Med. Chem. 45 (2002) 3509
12. Sato N., Takahashi T., Shibata T., Haga Y., Sakuraba A., Hirose M., Sato M., Nonoshita K., Koike Y., Kitazawa H., Fujino N., Ishii Y., Ishihara A., Kanatani A., and Fukami T. J. Med. Chem. 46 (2003) 666
13. Elliot R.L., Oliver R.M., LaFlamme J.A., Gillaspy M.L., Hammond M., Hank R.F., Maurer T., Baker D.L., DaSilva-Jardine P.A., Stevenson R.W., Mack C.M., and Casella J.V. Bioorg. Med. Chem. Lett. 13 (2003) 3593
14. Guba W., Neidhart W., and Nettekoven M. Bioorg. Med. Chem. Lett. 15 (2005) 1599
15. Gillman K.W., Higgins M.A., Poindexter G.S., Browning M., Clarke W.J., Flowers S., Grace Jr. J.E., Hogan J.B., McGovern R.T., Iben L.G., Mattson G.L., Ortiz A., Rassnick S., Russell J.W., and Antal-Zimanyi I. Bioorg. Med. Chem. 14 (2006) 5517
16. Takahashi T., Sakuraba A., Hirohashi T., Shibata T., Hirose M., Haga Y., Nonoshita K., Kanno T., Ito J., Iwaasa H., Kanatani A., Fukami T., and Sato N. Bioorg. Med. Chem. 14 (2006) 7501
17. Li G., Stamford A.W., Huang Y., Cheng K.-C., Cook J., Farley C., Gao J., Ghibaudi L., Greenlee W.J., Guzzi M., van Heek M., Hwa J.J., Kelly J., Mullins D., Parker E.M., Wainhaus S., and Zhang X. Bioorg. Med. Chem. Lett. 18 (2008) 1146
18. Ogino Y., Ohtake N., Nagae Y., Matsuda K., Moriya M., Suga T., Ishikawa M., Kanesaka M., Koike Y., Ito J., Kanno T., Ishihara A., Iwaasa H., Ohe T., Kanatani A., and Fukami T. Bioorg. Med. Chem. Lett. 18 (2008) 5010
19. Fukami, T.; Kanatani, A.; Ishihara, A.; Ishii, Y.; Takahashi, T.; Haga, Y.; Sakamoto, T.; Itoh, T. PCT Int. Appl. WO 200114376.
20. Orlek B.S., Blaney F.E., Brown F., Clark M.S.G., Hadley M.S., Hatcher J., Riley G.J., Rosenberg H.E., Wadsworth H.J., and Wyman P.J. Med. Chem. 34 (1991) 2726
21. 50 of this compound is 1.8 ± 0.2 nM.
22. 7.4 by utilizing PALLAS prologD, version 3.0, CompuDrug international Inc., CA, US.
23. Yalkowsky S.H., and Valani S.C. J. Pharm. Sci. 69 (1980) 912
24. Smith D.A., Jones B.C., and Walker D.K. Med. Res. Rev. 16 (1996) 243
25. H, u int.: mL/min/kg) using rat hepatocytes. Shibata Y., Takahashi H., and Ishii Y. Drug Metab. Dispos. 28 (2000) 1518 were D, D for 2n, A, A for 2r, B, C for 2s, and A, B for 2u, respectively. The results suggested that the compounds (2r, 2s, and 2u) were metabolically more stable than 2n in rat hepatocytes.
26. 34NPY-induced food intake study in rats. Parker E.M., Balasubramaniam A., Guzzi M., Mullins D.E., Salisbury B.G., Sheriff S., Wittten M.B., and Hwa J. J. Peptides 21 (2000) 393